What does a retrospective analysis of XanADu offer? There wasn't any cognitive improvement shown from that trial (probably because the dose was too low). Can anyone explain what the retrospective analysis will show/achieve?
Yesterday's example of US $1Billion offer for an Alzeimers drug Biotech, page-45
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.50M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.6¢ | 2.4¢ | $326.7K | 12.88M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2665003 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 1590984 | 5 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| ACW (ASX) Chart |